# US 2020/0138934 A1 · Methods and compositions for preventing or ameliorating pseudomonas aeruginosa pulmonary infections

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2020/0138934 A1
- Document ID: US20200138934A1
- Status: Published application
- Kind: A1
- Application number: 16/591,599
- Filed: 2019-10-02
- Published: 2020-05-07
- Earliest claimed: 2018-10-03
- Assignees: The Administrators of the Tulane Educational Fund
- Applicants: The Administrators of the Tulane Educational Fund
- Inventors: Lisa Ann MORICI; Sarah Margaret BAKER
- Web page: https://patentgrep.com/patent/US20200138934A1

## CPC

- A61K 39/104: {Pseudomonadales, e.g.} Pseudomonas
- A61K 47/46: Ingredients of undetermined constitution or reaction products thereof, e.g. skin, bone, milk, cotton fibre, eggshell, oxgall or plant extracts
- A61K 9/0021: {Intradermal administration, e.g. through microneedle arrays or needleless injectors}
- A61K 9/08: Solutions {(composition of solutions A61K47/00)}
- A61K 39/0258: {Escherichia}
- A61K 2039/54: {characterised by the route of administration}
- A61K 2039/55544: {Bacterial toxins}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The invention provides methods and compositions for preventing or ameliorating pulmonary infections with Pseudomonas aeruginosa.

## Claims

### Claim 1

A method of preventing or ameliorating a Pseudomonas aeruginosa lung infection in a subject, said method comprising intradermally co-administering to said subject P. aeruginosa outer membrane proteins (OMPs) and an Escherichia coli heat-labile enterotoxin (LT) with mutations at R192G and L211A (“dmLT”).

### Claim 2 (depends on 1)

The method of claim 1, wherein said OMPs and said dmLT are co-administered in a single formulation.

### Claim 3 (depends on 1)

The method of claim 1, wherein said intradermal administration is by microneedles.

### Claim 4 (depends on 1)

The method of claim 1, wherein said P. aeruginosa OMPs comprise OprI.

### Claim 5 (depends on 1)

The method of claim 1, wherein said P. aeruginosa OMPs comprise OprF.

### Claim 6 (depends on 1)

The method of claim 1, wherein said P. aeruginosa OMPs comprise OprG and KatA.

### Claim 7 (depends on 1)

The method of claim 1, in which said P. aeruginosa OMPs and said dmLT are co-administered to a subject who does not have a P. aeruginosa lung infection.

### Claim 8 (depends on 7)

The method of claim 7, wherein said subject has cystic fibrosis.

### Claim 9 (depends on 7)

The method of claim 7, wherein said subject is on a ventilator.

### Claim 10 (depends on 1)

The method of claim 1, in which said P. aeruginosa OMPs and said dmLT are co-administered to a subject who has a P. aeruginosa lung infection.

### Claim 11 (depends on 10)

The method of claim 10, wherein said subject has cystic fibrosis.

### Claim 12 (depends on 10)

The method of claim 10, wherein said subject is on a ventilator.

### Claim 13

A composition for intradermal vaccination of a subject in need thereof, said composition comprising Pseudomonas aeruginosa outer membrane proteins (OMPs) and an Escherichia coli heat-labile enterotoxin (LT) with mutations at R192G and L211A (“dmLT”).

### Claim 14 (depends on 13)

The composition of claim 13, further comprising a pharmaceutically acceptable carrier.

### Claim 15 (depends on 14)

The composition of claim 14, further wherein said P. aeruginosa OMPs include OprI.

### Claim 16 (depends on 13)

The method of claim 13, wherein said P. aeruginosa OMPs comprise OprF.

### Claim 17 (depends on 13)

The method of claim 13, wherein said P. aeruginosa OMPs comprise OprG and KatA.
